Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Free Cash Flow (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Free Cash Flow for 6 consecutive years, with -$44.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 22.47% to -$44.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$235.9 million, a 6.08% increase, with the full-year FY2025 number at -$235.9 million, up 6.08% from a year prior.
  • Free Cash Flow was -$44.9 million for Q4 2025 at Relay Therapeutics, up from -$62.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $46.2 million in Q1 2021 to a low of -$89.3 million in Q4 2023.
  • A 5-year average of -$55.4 million and a median of -$59.2 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 306.23% in 2021, then crashed 212.57% in 2022.
  • Relay Therapeutics' Free Cash Flow stood at -$43.1 million in 2021, then plummeted by 37.66% to -$59.4 million in 2022, then crashed by 50.36% to -$89.3 million in 2023, then skyrocketed by 35.2% to -$57.9 million in 2024, then increased by 22.47% to -$44.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Free Cash Flow are -$44.9 million (Q4 2025), -$62.1 million (Q3 2025), and -$55.3 million (Q2 2025).